New study tracks Alhemo's Real-World safety in hemophilia patients

NCT ID NCT06831734

ENROLLING_BY_INVITATION Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 16, 2026 · Last updated Jun 23, 2026 · Updated 3 times

Summary

This study follows 30 people with hemophilia A or B (without inhibitors) in Japan who are already using Alhemo (concizumab) as part of their routine care. Researchers will monitor side effects and how well the drug works over about 2 years per person. The goal is to see if Alhemo remains safe and effective in everyday medical practice.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Arin Clinic Shonika_Pediatrics

Okinawa, 901-2132, Japan
Chiba university hospital_Pediatrics

Chiba, 260-8677, Japan
Fukaya Red Cross Hospital_Haematology

Saitama, 366-0052, Japan
Hamamatsu Medical Center_Pediatrics

Shizuoka, 432-8580, Japan
Hoshi General Hospital_Pediatrics

Fukushima, 963-8501, Japan
Hyogo Prefectural Amagasaki General Medical Center_Haematology

Hyōgo, 660-8550, Japan
Ishiyama Clinic

Yamagata, 992-0035, Japan
Iwata City Hospital_Haematology

Shizuoka, 438-8550, Japan
Kansai Medical University Hospital_Pediatrics

Osaka, 573-1191, Japan
Matsue red cross hospital_Pediatrics

Shimane, 690-8506, Japan
Miyagi Children's Hospital_Hematology-Oncology

Miyagi, 989-3126, Japan
Nagano Children's Hospital_Hematology-Oncology

Nagano, 399-8288, Japan
Nagano red cross hospital_Pediatrics

Nahano, 380-8582, Japan
Nanbu Medical Center & Children's Medical Center_Pediatric Hematology

Okinawa, 901-1193, Japan
National Center for Child Health and Development_Hematology

Tokyo, 157-8535, Japan
National Hospital Organization Awara Hospital_Hematology and Oncology

Fukui, 910-4272, Japan
Ogikubo Hospital_Blood Coagulation

Tokyo, 167-0035, Japan
Saitama Children's Med Centre_Hematology-Oncology

Saitama, 330-8777, Japan
Saitama Medical Univ. Hospital Saitama medical center_Department of Transfusion Medicine and Cell Therapy

Kawagoe, Japan
Saitama Medical Univ. Hospital Saitama medical center_Department of Transfusion Medicine and Cell Therapy

Saitama, 350-8550, Japan
St. Marianna Univ., Yokohama City Seibu HP, Pediatrics Dept,

Yokohama-shi, Kanagawa, 241-0811, Japan
St. Marianna University School of Medicine Hospital_Pediatrics

Kanagawa, 216-8511, Japan
University of the Ryukyus Hospital_Endocrinology and Metabolism, Hematology and Rheumatology

Okinawa, 901-2725, Japan

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Concizumab (Alhemo)

What this could lead to

If successful, this study could confirm that Alhemo is safe and effective for long-term use in people with hemophilia A or B without inhibitors, supporting its routine use.

What could go wrong

This is an observational study with only 30 participants, so results may not apply to everyone. It does not test a new treatment, just monitors existing use, and unexpected side effects could still emerge.

Conditions

The condition(s) this trial relates to.

hemophilia hemophilia A hemophilia B

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HAEMOPHILIA A, HAEMOPHILIA B